| Abstrakt: |
A recent study conducted by the Food and Drug Administration in Silver Spring, Maryland, focused on the development of non-neutralizing monoclonal antibodies against a pandemic GII.4 norovirus variant. The research highlighted the potential role of these antibodies in understanding immunity to norovirus infection and disease. While the antibodies were mostly non-neutralizing, they were deemed valuable tools for norovirus research and diagnostics. For more information, readers can refer to the original article published in Microbiology Spectrum. [Extracted from the article] |
